Zosano Pharma Current Ratio 2013-2021 | ZSAN

Zosano Pharma current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Zosano Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.02B $0.01B 2.09
2021-03-31 $0.03B $0.01B 1.98
2020-12-31 $0.04B $0.02B 2.46
2020-09-30 $0.04B $0.01B 3.35
2020-06-30 $0.01B $0.02B 0.68
2020-03-31 $0.02B $0.02B 0.93
2019-12-31 $0.01B $0.02B 0.42
2019-09-30 $0.01B $0.01B 0.52
2019-06-30 $0.02B $0.02B 1.23
2019-03-31 $0.01B $0.02B 0.79
2018-12-31 $0.02B $0.01B 2.07
2018-09-30 $0.03B $0.01B 5.40
2018-06-30 $0.04B $0.01B 4.68
2018-03-31 $0.01B $0.01B 0.52
2017-12-31 $0.01B $0.01B 1.28
2017-09-30 $0.02B $0.01B 2.26
2017-06-30 $0.03B $0.01B 3.25
2017-03-31 $0.04B $0.01B 3.99
2016-12-31 $0.02B $0.01B 1.56
2016-09-30 $0.02B $0.01B 2.38
2016-06-30 $0.02B $0.01B 2.64
2016-03-31 $0.03B $0.01B 3.63
2015-12-31 $0.04B $0.01B 5.42
2015-09-30 $0.04B $0.01B 6.79
2015-06-30 $0.04B $0.00B 11.64
2015-03-31 $0.06B $0.00B 15.57
2014-12-31 $0.00B $0.01B 0.12
2014-09-30 $0.00B $0.01B 0.28
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B 0.00
2012-12-31 $0.01B $0.00B 1.48
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.000B
Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company's lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00